| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $5,250,176 ) |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 Arlington Ave | Toledo | OH | 43614-2598 | LUCAS | USA | H7600732 | Ryan White Part C Outpatient EIS Program | 00 | 24 | HRSA | 3/6/2025 | $129,999 |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01HD104418 | Astrocyte insulin resistance-induced neuroendocrine defects in pubertal delay and hypogonadotropic hypogonadism | 001 | 4 | NIH | 4/24/2025 | $53,623 |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01HD104418 | Astrocyte insulin resistance-induced neuroendocrine defects in pubertal delay and hypogonadotropic hypogonadism | 000 | 4 | NIH | 1/21/2025 | $482,604 |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01AG083628 | Investigation of active kinome networks in Alzheimer's dementia. | 000 | 2 | NIH | 5/9/2025 | $681,233 |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01CA272760 | Enhancing chemotherapeutic efficacy in triple-negative breast cancer via DSTYK silence | 002 | 3 | NIH | 4/24/2025 | $118,756 |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01CA272760 | Enhancing chemotherapeutic efficacy in triple-negative breast cancer via DSTYK silence | 004 | 3 | NIH | 5/19/2025 | $119,133 |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01CA272760 | Enhancing chemotherapeutic efficacy in triple-negative breast cancer via DSTYK silence | 001 | 3 | NIH | 3/25/2025 | $217,702 |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01HL178459 | Novel cysteinyl leukotriene receptor signaling in regulating cellular, and molecular events in lung inflammation | 000 | 1 | NIH | 6/9/2025 | $579,309 |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01DK133203 | Role of GSK3beta in diabetic kidney disease | 000 | 4 | NIH | 6/26/2025 | $339,900 |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R56MH139698 | Serotonin-mediated reorganization of the adolescent medial prefrontal cortex | 000 | 1 | NIH | 5/21/2025 | $545,759 |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01AG071332 | PPARG regulates osteocyte bioenergetics and function during aging | 000 | 5 | NIH | 6/3/2025 | $668,560 |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01NS122534 | Pre and post-synaptic pathways underlying the stress response in the adrenal medulla | 000 | 10 | NIH | 4/10/2025 | $370,154 |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01ES036248 | Developmental pyrethroid exposure in the prairie vole as a model of environmental risk for autism | 000 | 1 | NIH | 5/1/2025 | $605,550 |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R00DA055064 | Investigating the long-term effects of prenatal circadian rhythm disruption on substance use-related disorders | 000 | 3 | NIH | 3/4/2025 | $248,996 |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01DK134053 | Role of neutrophil extracellular traps (NETs) in Inflammatory bowel disease | 001 | 3 | NIH | 6/11/2025 | $43,012 |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01DK134053 | Role of neutrophil extracellular traps (NETs) in Inflammatory bowel disease | 000 | 3 | NIH | 2/20/2025 | $387,115 |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R03CA286634 | TAZ-driven Regulation of Tumor Microenvironment in Triple-Negative Breast Cancer | 002 | 3 | NIH | 12/23/2024 | $78,125 |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01CA286189 | Dormancy mimicking to inhibit prostate cancer metastasis progression and recurrence | 001 | 1 | NIH | 4/10/2025 | -$636,185 |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01CA286189 | Dormancy mimicking to inhibit prostate cancer metastasis progression and recurrence | 000 | 1 | NIH | 1/24/2025 | $636,185 |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01CA288278 | Molecular basis and targeting of FASN in expanding PARPi utility for TNBC | 000 | 1 | NIH | 12/19/2024 | $524,419 |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R03ES036303 | SWI/SNF in ultraviolet radiation-induced chromatin alterations | 000 | 1 | NIH | 12/19/2024 | $156,250 |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R00HL153896 | YAP1, neointima formation, and blood pressure regulation | 000 | 5 | NIH | 11/27/2024 | $249,000 |
| | 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R21AG091047 | Mechanistic tRNA modification affects to aging | 000 | 1 | NIH | 11/14/2024 | $430,603 |
| | 2025 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01AI184880 | Determining role of 14-3-3zeta in IL-17A signaling | 002 | 1 | NIH | 6/17/2025 | -$638,677 |
| | 2025 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01AI184880 | Determining role of 14-3-3zeta in IL-17A signaling | 000 | 1 | NIH | 6/12/2025 | $0 |
| | 2025 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R21DA055558 | Zebrafish Screens to Identify Agents which Reverse the Effects of Synthetic Opioids | 000 | 2 | NIH | 6/16/2025 | $0 |
| | 2025 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | T32GM144873 | Training in Molecular and translational Cell Dynamics | 000 | 3 | NIH | 5/29/2025 | $0 |
| | 2025 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01HL152162 | Neural mechanisms of host-microbiota interaction in hypertension: a potential for bio-electronic medicine | 000 | 4 | NIH | 4/24/2025 | $0 |
| | 2025 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01HL152162 | Neural mechanisms of host-microbiota interaction in hypertension: a potential for bio-electronic medicine | 002 | 4 | NIH | 5/7/2025 | -$393,908 |
| | 2025 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01CA230744 | Influence of bone microenvironment on drug resistance in prostate cancer bone metastasis | 000 | 6 | NIH | 1/9/2025 | $0 |
| | 2025 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R03CA286634 | TAZ-driven Regulation of Tumor Microenvironment in Triple-Negative Breast Cancer | 001 | 2 | NIH | 12/20/2024 | $14,777 |
| | 2025 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | U7723072 | Area Health Education Centers Point of Service Maintenance and Enhancement | 02 | 14 | HRSA | 5/7/2025 | $0 |
| | 2025 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | U7723072 | Area Health Education Centers Point of Service Maintenance and Enhancement | 01 | 14 | HRSA | 3/31/2025 | $0 |
| | 2025 | 2023 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | K01AA029763 | Targeting PI3K/BRD4 and Hedgehog Pathway in Alcohol Associated Liver Disease | 002 | 4 | NIH | 2/19/2025 | $7,506 |
| | 2025 | 2023 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R35GM150588 | Control of Klebsiella capsule biosynthesis and attachment | 000 | 1 | NIH | 2/28/2025 | -$180,607 |
| | 2025 | 2023 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R21MH125277 | A large sample machine learning network analysis of vertex cortical thickness measures for high resolution definition of PTSD related cortical structure abnormalities | 000 | 2 | NIH | 1/13/2025 | $0 |
| | 2025 | 2023 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R21CA256462 | Targeting of eIF4A along with immunotherapy to overcome chemoresistance | 000 | 2 | NIH | 6/11/2025 | -$39 |
| | 2025 | 2023 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01AI144115 | Integration of Leukotriene and Prostaglandin Receptor Signaling in Mast cell Activation and Pulmonary Inflammation during Asthma | 000 | 6 | NIH | 6/9/2025 | -$449 |
| | 2025 | 2023 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R21MH127500 | The effect of SHANK3 mutation in transgenic prairie voles on natural social behaviors and genetic mechanisms | 000 | 2 | NIH | 4/8/2025 | -$6,970 |
| | 2025 | 2023 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01DE027343 | The role of platelets in protection against oral candidiasis | 000 | 5 | NIH | 5/5/2025 | -$64 |
| | 2025 | 2022 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01CA211904 | Molecular targeting the translational control axis in Wnt/beta-catenin signaling pathway | 000 | 6 | NIH | 3/14/2025 | -$191 |
| | 2025 | 2022 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01AI155545 | Anti-inflammatory functions for non-transcriptional IRF3 | 001 | 2 | NIH | 2/12/2025 | -$428,039 |
| | 2025 | 2022 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01CA219342 | ATR Isomerization in Cellular Responses to UV Damage of DNA | 000 | 6 | NIH | 1/2/2025 | -$46,868 |
| | 2025 | 2022 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01AG057598 | Development of Attenuated Furoxans as Novel Therapies for Alzheimer's Disease | 000 | 5 | NIH | 6/13/2025 | -$11,634 |
| | 2025 | 2022 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01AI165521 | Novel antiviral mechanisms of the interferon system | 000 | 1 | NIH | 10/21/2024 | -$94,462 |
| | 2025 | 2021 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01DK114006 | The Melanocortinergic pathway inglomerular disease | 000 | 6 | NIH | 11/7/2024 | -$1 |
|
| Issue Date FY: 2024 ( Subtotal = $14,448,701 ) (Continued on the next page) |
| | 2024 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R00HL153896 | YAP1, neointima formation, and blood pressure regulation | 001 | 4 | NIH | 6/26/2024 | $24,899 |
| | 2024 | 2024 | UNIVERSITY OF TOLEDO | 3000 Arlington Ave | Toledo | OH | 43614-2598 | LUCAS | USA | H1224838 | Ryan White Title IV Women, Infants, Children, Youth and Affected Family Members AIDS Healthcare | 00 | 12 | HRSA | 7/1/2024 | $507,781 |
|
